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Introduction: Chemotherapy and other systemic therapies are the primary treatments for patients with
unresectable, locally advanced breast cancer. The clinical application of supportive care using Mohs paste has
become widespread for the purpose of improving patients’ quality of life. Here, we report two cases of locally
advanced breast cancer, for which the patients underwent radical surgery after a combination of systemic therapy
and Mohs chemosurgery.
Case presentations: Patient 1 was a 90-year-old Japanese woman with right breast cancer diagnosed as stage IIIB
(T4bN1M0). The treatment included Mohs paste application and hormonal therapies. Patient 2 was a 60-year-old
Japanese woman with right breast cancer diagnosed as stage IIIB (T4cN2aM0). Her treatment included Mohs paste
application, together with chemotherapy (four cycles of 5-fluorouracil, epirubicin, and cyclophosphamide, and four
cycles of docetaxel). In both cases, a reduction in the primary tumor volume was observed, and radical mastectomy
and axillary lymph node dissection were possible without relaxation incision or skin flap.
Conclusion: We report patients with no distant metastases who were able to undergo radical resection after a
combination of systemic therapy and Mohs chemosurgery. For locally advanced breast cancer, Mohs chemosurgery,
in addition to multidisciplinary treatment, is useful.
Keywords: Breast cancer, Modified radical mastectomy, Mohs surgeryIntroduction
For patients with unresectable, locally advanced breast
cancer with skin invasion, the primary therapy is systemic,
such as chemotherapy [1]. However, the presence of bleed-
ing, exudates, and/or strong odor from infection can
adversely impact quality of life (QOL). These symptoms are
collectively referred to as malignant wounds and are mana-
ged with palliative treatment [2,3]. Patients with breast,
head and neck, and primary skin cancers have the highest
prevalence of malignant wounds (47.1%, 46.7%, and 39.1%
of patients, respectively) [4], and Mohs chemosurgery has
been applied for such patients [5-7]. Mohs chemosurgery is
a technique of chemical fixation of a cutaneous tumor and* Correspondence: tkd_tmy@nifty.com
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reproduction in any medium, provided the orsubsequent excision [8,9]. The fixative used in a Mohs
procedure contains zinc chloride and is referred to as Mohs
paste. In this technique, fixation and excision are repeated
until no residual tumor can be found in the specimen by
microscopic examination [10]. In recent years, the use of
Mohs chemosurgery has become widespread for the
primary purpose of improving QOL. However, in patients
with breast cancer, there is little reported experience with
the application of Mohs paste for the purpose of tumor
reduction. To the best of our knowledge, there are no
reports of patients who underwent radical surgery after a
combination of systemic therapy and Mohs chemosurgery.
Here, we report two cases of locally advanced breast cancer
for which the patients underwent radical surgery after a
combination of systemic therapy and Mohs chemosurgery.
Furthermore, as frequent dressing changes are necessary
due to exudates from ulcers after Mohs chemosurgery, we
report easy management of these issues in the out-patient
setting by an appropriate choice of wound dressing.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Protocol for the Mohs method in our hospital
1. Apply petroleum jelly to the surrounding normal skin,
and cover with gauze to protect from Mohs paste.
2. Uniformly apply the Mohs paste at a thickness of 1mm
on the surface of tumor and protect using gauze.
3. Remove the gauze and Mohs paste 24 hours after application.
4. After removal of Mohs paste, apply petroleum jelly and
protect using gauze.
5. Observe the tumor at the same time every day. Necrotic
tissue may be removed bluntly, or it might fall off naturally.
6. Continue above cycle every 2–3 days until the elevated
tumor is flattened.
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Pharmaceutical Affairs in our hospital and written
informed consent from the patients, we obtained Mohs
paste formulated by the pharmaceutical department.
Zinc chloride was ground into a powder in a mortar and
dissolved using purified water. Next, zinc oxide starch
powder was mixed gradually. Finally, glycerin was added
to a viscosity individualized according to the patient’s
need (Table 1). Mohs paste was formulated on the day
of use. After petroleum jelly was applied to the
surrounding normal skin, Mohs paste was applied to the
tumor and covered with gauze. Mohs paste was removed
24 hours after application, and petroleum jelly was
reapplied. Gauze was changed every day. Necrotic tissue
was removed bluntly. This method was repeated until
the tumor flattened (Table 2).
Case presentations
Patient 1
A 90-year-old Japanese woman presented with back
pain, and a right breast mass was found at that time. She
had been aware of bleeding from the breast mass for the
past 5 years. The mass was an 8cm-diameter tumor of
the right breast, measured from the nipple laterally and
including the central portion of the breast. There was in-
filtration into the skin, but no fixation to the chest wall
was observed (Figure 1a). She also reported tenderness
in the thoracic vertebrae. A computed tomography (CT)
scan revealed a huge mass in the right breast with
overlying and surrounding skin thickening (Figure 1b).
A swollen axillary lymph node and a compression frac-
ture in the twelfth thoracic vertebra were also observed.
Magnetic resonance imaging (MRI) was also performed
for the vertebra and neoplastic lesions were not obvious.
A core needle biopsy was performed, and histopathologic
examination of the biopsy specimen revealed invasive
micropapillary carcinoma, estrogen receptor (ER)-positive,
progesterone receptor (PgR)-positive, and human epider-
mal growth factor receptor 2 (HER2)-1+. ER, PgR and
HER2 status was determined using immunohistochemical
examination and/or fluorescence in situ hybridization
(FISH). ER and PgR results were considered positive withTable 1 Formulation of Mohs paste
Material Original methoda Our hospital
Saturated zinc chloride 34.5mL
Zinc chloride 10g
Purified water 10mL
Powdered Sanguinaria canadensis 10g
Zinc oxide starch powder 5g
Paste containing stibnite 40g
Glycerin 5–10mL
aOriginal method [8,9].≥10% positively staining cells. HER2 was considered posi-
tive with either 3+ immunoreactivity or amplification by
FISH in accordance with the American Society of Clinical
Oncology-College of American Pathologists guideline
[11]. Positron emission tomography (PET)-CT was per-
formed, and the final diagnosis was breast cancer, stage
IIIB (T4bN1M0).
The patient was hospitalized, with bedrest as treatment
for the compression fracture, and letrozole was selected as
systemic therapy for the breast cancer. Alendronate,
calcium L-aspartate and alfacalcidol were also administered.
Written informed consent was obtained from the patient,
and Mohs paste was applied to control local bleeding and
exudates. After using Mohs paste for three cycles, the
tumor flattened, and there was no further need for daily
dressing changes. VersivaW XCW (ConvaTec Japan, Tokyo,
Japan), which contains hydrocolloid and hydrofiber, was
used for wound closure [12]. The VersivaW XCW dressing
required once-weekly dressing changes. The wound could
be left uncovered starting on day 28 from the first Mohs
chemosurgery. Letrozole was continued for approximately
6 months in the out-patient setting. The skin infiltration
reduced gradually (Figures 1c, 1d). Radical mastectomy of
the right breast and axillary lymph node dissection (level 1)
were performed. The infiltrated skin was resected at the
same time, without the need for relaxation incision or skin
flap. Histologic examination showed mucinous carcinoma
with lymph node metastasis (metastatic axillary lymph
nodes/dissected lymph nodes: 3/26); the histologic evalu-
ation of the therapeutic effect was grade 1b. The patient
was discharged on postoperative day 16 without any post-
operative complications. She has continued oral letrozole
since her surgery of 15 months ago.
Patient 2
A 60-year-old Japanese woman presented with a right
breast mass with exudates. She had been aware of the
breast mass for the past 5 years. A 5cm-diameter tumor
was present in the superior-lateral quadrant of the right
breast. Exposure to the skin and fixation to the chest
wall were observed (Figure 2a). Hard axillary lymph
  
Figure 1 Case 1. a: Macroscopic image of the right breast at the initial visit. b: Computed tomography (CT) findings at the initial visit. CT
revealed a mass with overlying and surrounding skin thickening (arrowheads). c: Macroscopic image of the right breast before surgical treatment.
d: CT findings before surgical treatment.
Figure 2 Case 2. a: Macroscopic image of the right breast at the initial visit. b: Computed tomography (CT) findings at the initial visit. CT
revealed a mass with infiltration of the pectoralis major muscle (arrowheads). c: Macroscopic image of the right breast before surgical treatment.
d: CT findings before surgical treatment.
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the right breast with infiltration of the pectoralis major
muscle (Figure 2b). Swollen axillary lymph nodes were
also observed. A core needle biopsy was performed, and
histopathologic examination of the biopsy specimen
revealed invasive papillotubular carcinoma, ER-positive,
PgR-positive, and HER2-negative. PET-CT was performed,
and the final diagnosis was breast cancer, stage IIIB
(T4cN2aM0). In addition, idiopathic thrombocytopenia
and chronic hepatitis C were diagnosed at this visit.
She underwent four cycles of 5-fluorouracil 500mg/m2,
epirubicin 100mg/m2, and cyclophosphamide 500mg/m2
(FEC100) and four cycles of docetaxel (75mg/m2) as
neoadjuvant chemotherapy. Chemotherapy was initiated
with an 80% dose reduction due to pancytopenia from
idiopathic thrombocytopenia and chronic hepatitis C.
Thereafter she was able to complete therapy without
cessation or further reduction of chemotherapy drugs.
Written informed consent was obtained from the patient,
and Mohs paste was applied for exudates. After using
Mohs paste for three cycles, the wound was closed with
VersivaW XCW on day 15 from the first Mohs chemosur-
gery. Although she could have been discharged from the
hospital before her the third course of FEC100, weekly
dressing changes of the VersivaW XCW were required.
After neoadjuvant therapy was changed to docetaxel,
tumor reduction occurred slowly, and the tumor did not
epithelialize (Figure 2c). After completion of chemotherapy,
invasion of the pectoralis major muscle was still present
(Figure 2d). Radical mastectomy of the right breast and
axillary lymph node dissection (level 2) were performed.
The invaded portions of the pectoralis major and pectoralis
minor muscles were also resected. Relaxation incision or
skin flap was not required. Histologic examination showed
papillotubular carcinoma with lymph node metastasis
(metastatic axillary lymph nodes/dissected lymph nodes:
4/17), and the histologic evaluation of therapeutic effect
was grade 1b. The patient was discharged on postoperative
day 24 without any postoperative complications. She
began oral letrozole 9 months ago after her surgery.
Discussion
Mohs chemosurgery is minimally invasive and relatively
simple. This method has been applied widely in areas
such as palliative care and is considered a very useful
treatment [7]. Although no guiding philosophy exists
regarding the use interval and contact time with Mohs
paste, the progress and depth of consolidation depend
on contact time. Reported contact times range from a
few minutes to 48 hours [10]. Hemostatic effects have
been seen with times ranging from a few minutes to 10
minutes [7]. The intended purpose of Mohs paste appli-
cation is to determine the appropriate use interval and
contact time. When using Mohs paste, it is important toprotect normal, healthy skin. Several methods for
containing the oil, such as thick application of petroleum
jelly or affixing dressing agents, have been applied [7].
For the formulation of Mohs paste, a saturated solution
of zinc chloride (purified water:zinc chloride, 1mL:2g)
was made, then mixed with zinc oxide starch powder,
and the viscosity was adjusted using glycerin. This
preparation method allowed the production of a roughly
common product. With the aim of tumor reduction, a
relatively long contact time (24 hours) was determined
and the concentration was reduced to 50%, instead of a
saturated solution, for the purpose of achieving slow
infiltration. Tissue fixation can be obtained even at
concentrations of 50%; therefore, a saturated solution
was deemed unnecessary. After using Mohs paste, nec-
rotic tissue is formed. In many cases, necrotic tissue is
removed bluntly, without local anesthesia, or it falls off
naturally. After removal, an ulcer might form, and exu-
dates might reduce; however, regular dressing changes
remain necessary.
Closure therapy was performed according to pressure
ulcer protocol using VersivaW XCW. VersivaW XCW is an
adhesive patch, with reported effectiveness; it creates a
moist environment to promote wound healing and can
protect the surrounding environment by containing the
exudate [13]. Daniels et al. demonstrated ease-of-use
and no problems with use of the patch for an average of
between 5 and 6 days [14]. Similarly, the present patients
experienced no problems with weekly dressing changes
in the out-patient setting. Complete epithelialization was
achieved in Case 1. In Case 2, complete closure was not
achieved due to a decline in the antitumor effects of
docetaxel, but weekly dressing changes could be continued
without complications such as infection. VersivaW XCW is
a useful dressing in the out-patient setting.
In breast cancer treatment, few experiences have been
reported with the primary goal of cytoreduction. To the
best of our knowledge, radical surgery after a combination
of systemic therapy and Mohs chemosurgery has not been
reported. In skin tumor resection, Mohs chemosurgery is
not a first-line choice, but good results have also been
reported [5,15,16]. For patients with locally advanced breast
cancer, multidisciplinary treatment should be applied.
However, Mohs chemosurgery can aid in tumor reduction
when combined with multidisciplinary treatment in
patients with no distant metastases. In particular, Mohs
chemosurgery is a useful method in patients with bleeding
and exudates.
Conclusions
This report demonstrates that for patients with no distant
metastases, radical resection through a combination of
systemic therapy and Mohs chemosurgery is useful. Mohs
paste resulted in tumor reduction, and wound closure was
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allowed a simple suture closure of the dermis.
For locally advanced breast cancer, Mohs chemosurgery,
in addition to multidisciplinary treatment, is a useful
approach.
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